ClinicalTrials.gg
TerminatedNCT03435640REVEALUpdated Mar 8, 2023Results posted

REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

A Phase 1/2 interventional study of NKTR-262 and bempegaldesleukin in Melanoma, Merkel Cell Carcinoma and Triple Negative Breast Cancer, sponsored by Nektar Therapeutics. Terminated at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-08.

Sponsored by Nektar Therapeutics · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons.
Phase
Phase 1/2
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable toxicity, death, or disease progression per RECIST 1.1. Based on Phase 1 results of the study, the decision was made not to start the Phase 2 part of the study and the study was terminated.

Read the detailed description

Cancer treatments that couple pharmacological activation of tumor antigen presentation with activation and expansion of CD8+ T and natural killer (NK) cells in the tumor environment have the potential to induce an effective anti-tumor immune response in patients. NKTR-262 is a small molecule agonist of toll-like receptors (TLRs) 7/8 designed to be retained in the tumor micro-environment in order to activate antigen-presenting cells (APC), such as dendritic cells, to create new antigen-specific cytotoxic T cells. As a CD122-biased agonist, bempegaldesleukin monotherapy increases newly proliferative CD8+ T cells in tumors. NKTR-262 plus bempegaldesleukin is expected to increase expansion of antigen-specific CD8+ T cells. In preclinical studies, a single IT injection of NKTR-262 plus IV bempegaldesleukin resulted in complete abscopal effects in tumor models. Preliminary clinical data show bempegaldesleukin plus nivolumab enhances immune-stimulatory responses. The REVEAL trial will assess safety and anti-tumor activity of NKTR-262 with bempegaldesleukin +/- nivolumab for the treatment of selected cancers.

  • Melanoma (1st-line and relapsed/refractory)
  • Merkel Cell Carcinoma (2nd-line and relapsed/refractory)
  • Triple Negative Breast Cancer (1st- and 2nd-line and relapsed/refractory)
  • Renal Cell Carcinoma (1st-line and relapsed/refractory)
  • Colorectal Cancer (2nd-line and relapsed/refractory; MSI non-high)
  • Colorectal Cancer (2nd 3rd-line+, I-O therapy naive; relapsed/refractory; MSI high)
  • Head and Neck Squamous Cell Carcinoma (2nd-line and relapsed/refractory)
  • Sarcoma (2nd-line and relapsed/refractory)
02

Conditions studied

  • Melanoma
  • Merkel Cell Carcinoma
  • Triple Negative Breast Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Renal Cell Carcinoma
  • Colorectal Cancer
  • Sarcoma

Keywords

  • Bempegaldesleukin (NKTR-214)
  • NKTR-262
  • Nivolumab
  • Opdivo®
  • Metastatic
  • Locally advanced
  • Relapsed/Refractory
  • TLR7/8
  • CD122
03

In context

Melanoma

3,370 studies on the registry are indexed under Melanoma; 578 are open to participants now.

This study's enrollment of 64 is above the median of 40 across 2,649 interventional studies indexed under Melanoma.

Browse Melanoma studies →

Lead sponsor

Nektar Therapeutics is the lead sponsor of 39 studies on the registry; 2 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 13 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed diagnosis of a locally advanced (not amenable to curative therapy such as surgical resection) cancer of the following histologies: melanoma (MEL), Merkel cell carcinoma (MCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), colorectal cancer, head and neck squamous cell carcinoma (HNSCC), or sarcoma.
  • > 12 weeks as determined by the Investigator.
  • (ECOG) performance status 0 or 1.
  • per 1.1.
  • Patients enrolled in Cohorts 1-10, Cohort A, Cohort B and Phase 2 Doublet must be to all therapies known to confer clinical benefit to their disease.
  • Fresh tumor tissue available for cellular characterization and programmed cell death protein 1 () status.
  • Injected lesions (up to two) must be between 20 mm and 90 mm in diameter for IT injection; lesions must be accessible for baseline and on-treatment . Any liver lesion targeted for injection must not exceed 50 mm at the time of injection.
  • Demonstrated adequate organ function within 14 days of Cycle 1 Day 1 (C1D1).

Key Exclusion Criteria:

  • Use of an agent or an investigational device within 21 days before administration of first dose of study drug(s).
  • Patients treated with prior interleukin-2 (IL-2).
  • Patients who have been previously treated with a toll-like receptor (TLR) agonist (excluding topical agents) and patients who have received experimental cancer vaccines.
  • Patients who have received systemic interferon (IFN)α within the previous 6 months prior to enrollment to the study.
  • Other active , except non-melanomic skin cancer
  • Evidence of interstitial lung disease or active, noninfectious pneumonitis.
  • Prior surgery or radiotherapy within 14 days of initiating study drug(s). Patients must have recovered from all radiation-related toxicities, not required and have not had radiation pneumonitis.
  • Prolonged Fridericia's interval (QTcF) > 450 ms for men and > 470 ms for women at Screening.

History of unstable or deteriorating cardiac disease within the previous 6 months prior to screening including but not limited to the following:

  • Unstable angina or myocardial infarction.
  • Congestive heart failure ( Class III or IV).
  • Uncontrolled clinically significant arrhythmias.
  • Patients with a history of any retinal disorders (e.g., retinal detachment, diabetic retinopathy, retinal hemorrhage, macular degeneration).
  • Uveal melanoma will be excluded
  • Patients with tumor that invade the superior vena cava or other major blood vessels.

Additional general and tumor specific inclusion and exclusion criteria will apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    NKTR-262 + bempegaldesleukin or + bempegaldesleukin with nivolumab

    Phase 1: NKTR-262 in escalating doses, combined with bempegaldesleukin. The goal of this dose escalation part of the study is to establish a recommended Phase 1b dose for NKTR-262 + bempegaldesleukin with nivolumab, followed by a dose-confirmation cohort.

    Drug: NKTR-262 · Drug: bempegaldesleukin · Drug: nivolumab

Interventions

  • DrugNKTR-262

    During Phase 1 Doublet: Patients receive escalating doses of NKTR-262 IT (starting dose 0.03 mg) in 3-week treatment cycles. During Phase 1 Doublet (Cohort A), Phase 2 Doublet: Patients were to receive the RP2D of NKTR-262. During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients receive the RP2D of NKTR-262.

  • During Phase 1 Doublet (Cohort A), and proposed Phase 2 Doublet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles. During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.

    Also known as: NKTR-214

  • During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive a nivolumab flat dose of 360 mg administered in 3-week treatment cycles.

    Also known as: Opdivo®

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Dose-Limiting Toxicities (DLTS)

    DLTs were assessed in Cohort 1 through Cohort 9, which had dose levels of NKTR-262 as 0.03mg, 0.06mg, 0.06mg, 0.12mg, 0.24mg, 0.48mg, 0.96mg, 1.92mg, and 3.84mg in combination with bempegaldesleukin (bempeg). There was only 1 DLT that occurred in one of the Cohort 9 patients. Therefore, the maximum tolerated dose (MTD) of NKTR 262 was not reached.

    Time frame: The DLT window is 21 days following NKTR-262 single agent administration (Cycle 1) and an additional 9 days when combined with bempeg for staggered dosing administration (Cohorts 1 and 2), or 7 days for the same day administration (Cohort 3 and higher).

  2. Objective Response Rate (ORR) Per RECIST 1.1 in Cohort A and Cohort B at Recommended Phase 2 Dose (RP2D)

    Objective Response Rate (ORR) per RECIST 1.1 in Cohort A and Cohort B at Recommended Phase 2 Dose (RP2D). ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 and as assessed by Blinded Independent Central Review (BICR).

    Time frame: From Cycle 1 Day 1 to 100 days after the last dose of study drug or the date for new anti-cancer therapy, whichever is earlier.

07

Results

Posted Mar 8, 2023

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered)Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered)Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab
Started3343444381414
Completed3231441381211
Not completed01120030023
Withdrew: Withdrawal by subject01020030023
Withdrew: Lost to follow-up00100000000

Outcome measures

PrimaryNumber of Participants Experiencing Dose-Limiting Toxicities (DLTS)

DLTs were assessed in Cohort 1 through Cohort 9, which had dose levels of NKTR-262 as 0.03mg, 0.06mg, 0.06mg, 0.12mg, 0.24mg, 0.48mg, 0.96mg, 1.92mg, and 3.84mg in combination with bempegaldesleukin (bempeg). There was only 1 DLT that occurred in one of the Cohort 9 patients. Therefore, the maximum tolerated dose (MTD) of NKTR 262 was not reached.

Time frame:
The DLT window is 21 days following NKTR-262 single agent administration (Cycle 1) and an additional 9 days when combined with bempeg for staggered dosing administration (Cohorts 1 and 2), or 7 days for the same day administration (Cohort 3 and higher).
Reported as:
Count of participants · Participants
Number of Participants Experiencing Dose-Limiting Toxicities (DLTS)
ParticipantsCohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered)Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered)Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab
Number of Participants Experiencing Dose-Limiting Toxicities (DLTS)00000000100
PrimaryObjective Response Rate (ORR) Per RECIST 1.1 in Cohort A and Cohort B at Recommended Phase 2 Dose (RP2D)

Objective Response Rate (ORR) per RECIST 1.1 in Cohort A and Cohort B at Recommended Phase 2 Dose (RP2D). ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 and as assessed by Blinded Independent Central Review (BICR).

Time frame:
From Cycle 1 Day 1 to 100 days after the last dose of study drug or the date for new anti-cancer therapy, whichever is earlier.
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Per RECIST 1.1 in Cohort A and Cohort B at Recommended Phase 2 Dose (RP2D)
percentage of participantsCohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab
Objective Response Rate (ORR) Per RECIST 1.1 in Cohort A and Cohort B at Recommended Phase 2 Dose (RP2D)0 (0.0 to 23.2)14.3 (1.8 to 42.8)

Adverse events

Collected over 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered)2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered)2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day)3/4 (75%)1/4 (25%)4/4 (100%)
Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day)1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day)4/4 (100%)1/4 (25%)4/4 (100%)
Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day)4/4 (100%)1/4 (25%)4/4 (100%)
Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day)1/4 (25%)1/4 (25%)4/4 (100%)
Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day)2/3 (66.7%)3/3 (100%)3/3 (100%)
Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)5/8 (62.5%)3/8 (37.5%)8/8 (100%)
Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)9/14 (64.3%)2/14 (14.3%)14/14 (100%)
Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab5/14 (35.7%)5/14 (35.7%)14/14 (100%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventCohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered)Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered)Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab
SyncopeNervous system disorders0/30/30/40/30/40/40/41/30/81/140/14
Cerebral infarctionNervous system disorders0/30/30/40/30/40/40/41/30/80/140/14
Haemorrhage intracranialNervous system disorders1/30/30/40/30/40/40/40/30/80/140/14
Upper gastrointestinal haemorrhageGastrointestinal disorders0/31/30/40/30/40/40/40/30/80/140/14
AnaemiaBlood and lymphatic system disorders1/30/30/40/30/40/40/40/30/80/141/14
PneumothoraxRespiratory, thoracic and mediastinal disorders0/30/30/40/30/40/40/41/30/80/140/14
Cytokine release syndromeImmune system disorders0/30/30/40/30/40/40/41/30/80/140/14
Amylase increasedInvestigations0/30/30/41/30/40/40/40/30/80/140/14
Lipase increasedInvestigations0/30/30/41/30/40/40/40/30/80/140/14
NephrolithiasisRenal and urinary disorders0/30/30/40/30/40/40/41/30/80/140/14
Most frequent other events
Showing 10 of 245
Most frequent other events
EventCohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered)Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered)Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab
FatigueGeneral disorders2/33/32/41/33/42/43/41/34/88/146/14
PyrexiaGeneral disorders0/32/32/41/32/42/42/43/32/82/149/14
NauseaGastrointestinal disorders0/33/32/41/32/42/42/43/35/88/148/14
ChillsGeneral disorders0/31/31/41/33/41/40/40/31/81/145/14
Oedema peripheralGeneral disorders0/31/30/40/32/43/40/40/30/81/142/14
ArthralgiaMusculoskeletal and connective tissue disorders2/31/31/40/30/43/41/40/33/84/145/14
DizzinessNervous system disorders0/30/30/40/30/43/40/41/32/82/141/14
Influenza like illnessGeneral disorders2/30/32/41/32/42/40/41/35/88/146/14
DiarrhoeaGastrointestinal disorders2/30/31/41/32/42/41/41/33/87/146/14
VomitingGastrointestinal disorders0/32/30/42/31/41/40/41/35/84/145/14

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered)Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered)Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + NivolumabTotal
<=18 years000000000000
Between 18 and 65 years13222133810843
>=65 years2021231004621
Age, Continuous
Age, Continuous(years)Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered)Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered)Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + NivolumabTotal
Mean66.0 (63 to 69)53.0 (39 to 64)51.5 (32 to 71)56.3 (39 to 73)57.0 (41 to 74)68.0 (58 to 79)55.3 (40 to 72)59.0 (58 to 61)49.0 (35 to 63)57.7 (30 to 81)60.3 (28 to 79)57.4 (28 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered)Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered)Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + NivolumabTotal
Female1121221054726
Male22222233310738
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered)Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered)Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + NivolumabTotal
Hispanic or Latino000100000113
Not Hispanic or Latino334234438131360
Unknown or Not Reported000010000001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered)Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered)Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + NivolumabTotal
American Indian or Alaska Native000000000101
Asian000010100103
Native Hawaiian or Other Pacific Islander000000000000
Black or African American000000000101
White334334338111459
More than one race000000000000
Unknown or Not Reported000000000000
Region of Enrollment
Region of Enrollment(participants)Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered)Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered)Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + NivolumabTotal
United States334344438141464
ECOG Performance Status
ECOG Performance Status(Participants)Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered)Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered)Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day)Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + NivolumabTotal
ECOG 02121223367534
ECOG 11222221027930
08

Study locations

14 sites
  • HonorHealth
    Scottsdale, Arizona 85258, United States
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Winship Cancer Center, Emory University Hospital
    Atlanta, Georgia 30322, United States
  • University of Kansas Research Center
    Fairway, Kansas 66205, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Masonic Cancer Center, University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
09

References and documents

Publications

  • Rolig AS, Rose DC, McGee GH, Rubas W, Kivimae S, Redmond WL. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT. J Immunother Cancer. 2022 Apr;10(4):e004218. doi: 10.1136/jitc-2021-004218. PubMed 35444059 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03435640
Responsible party
Sponsor
First posted
Feb 19, 2018
Start date
Mar 15, 2018
Primary completion
May 9, 2022
Completion
May 9, 2022
Results posted
Mar 8, 2023
Last update
Mar 8, 2023

Study contacts

Study Director
study director · Nektar Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion